Niels van de Donk

DR.

20122019
If you made any changes in Pure these will be visible here soon.

Research Output 2012 2019

Filter
Article
2019

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H. L., Caillot, D., Corre, J., Delforge, M., Dejoie, T., Doyen, C., Facon, T., Sonntag, C. C., Fontan, J., Garderet, L., Jie, K-S., Karlin, L. & 38 othersKuhnowski, F., Lambert, J. R., Leleu, X., Lenain, P., Macro, M., Mathiot, C., Orsini-Piocelle, F., Perrot, A., Stoppa, A-M., van de Donk, N. W. CJ., Wuilleme, S., Zweegman, S., Kolb, B., Touzeau, C., Roussel, M., Tiab, M., Marolleau, J-P., Meuleman, N., Vekemans, M-C., Westerman, M., Klein, S. K., Levin, M-D., Fermand, J. P., Escoffre-Barbe, M., Eveillard, J-R., Garidi, R., Ahmadi, T., Zhuang, S., Chiu, C., Pei, L., de Boer, C., Smith, E., Deraedt, W., Kampfenkel, T., Schecter, J., Vermeulen, J., Avet-Loiseau, H. & Sonneveld, P., 2019, In : The Lancet. 394, 10192, p. 29-38

Research output: Contribution to journalArticleAcademicpeer-review

Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered t cells

Drent, E., Poels, R., Ruiter, R., van de Donk, N. W. C. J., Zweegman, S., Yuan, H., de Bruijn, J., Sadelain, M., Lokhorst, H. M., Groen, R. W. J., Mutis, T. & Themeli, M., 2019, In : Clinical Cancer Research. 25, 13, p. 4014-4025

Research output: Contribution to journalArticleAcademicpeer-review

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

van de Donk, N. W. C. J., Casneuf, T., Di Cara, A., Parren, P. W., Zweegman, S., van Kessel, B., Lokhorst, H. M., Usmani, S. Z., Lonial, S., Richardson, P. G., Chiu, C., Mutis, T., Nijhof, I. S. & Sasser, A. K., 1 Feb 2019, In : British Journal of Haematology. 184, 3, p. 475-479 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options

Amaador, K., Peeters, H., Minnema, M. C., Nguyen, T. Q., Dendooven, A., Vos, J. M. I., Croockewit, A. J., van de Donk, N. W. C. J., Jacobs, J. F. M., Wetzels, J. F. M., Sprangers, B. & Abrahams, A. C., 2019, In : Netherlands Journal of Medicine. 77, 7, p. 243-254

Research output: Contribution to journalArticleAcademicpeer-review

Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Holthof, L. C., van der Horst, H. J., van Hal-van Veen, S. E., Ruiter, R. W. J., Li, F., Buijze, M., Andersen, M. N., Yuan, H., de Bruijn, J., van de Donk, N. W. C. J., Lokhorst, H. M., Zweegman, S., Groen, R. W. J. & Mutis, T., 23 May 2019, In : Haematologica.

Research output: Contribution to journalArticleAcademicpeer-review

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Usmani, S. Z., Nahi, H., Mateos, M-V., van de Donk, N. W. C. J., Chari, A., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Hellemans, P., Masterson, T., Clemens, P. L., Luo, M., Liu, K. & San-Miguel, J., 2019, In : Blood. 134, 8, p. 668-677

Research output: Contribution to journalArticleAcademicpeer-review

2018

Case report: Persistently seronegative neuroborreliosis in an immunocompromised patient

Wagemakers, A., Visser, M. C., de Wever, B., Hovius, J. W., van de Donk, N. W. C. J., Hendriks, E. J., Peferoen, L., Muller, F. F. & Ang, C. W., 2018, In : BMC Infectious Diseases. 18, 1, 362.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Marin Soto, J., Broekmans, M., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C., Nijhof, I. S., Mutis, T., Zweegman, S., Lokhorst, H. M. & van de Donk, N. W. C. J., Mar 2018, In : Expert Review of Clinical Immunology. 14, 3, p. 197-206 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update

Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S. & Lokhorst, H. M., 1 Jan 2018, In : Drugs. 78, 1, p. 19-37 19 p.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when

Caers, J., Garderet, L., Kortüm, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., Dold, S. M., Gay, F., Corre, J., Beguin, Y., Ludwig, H., Larocca, A., Driessen, C., Dimopoulos, M. A., Boccadoro, M., Gramatzki, M., Zweegman, S., Einsele, H., Cavo, M., Goldschmidt, H. & 5 othersSonneveld, P., Delforge, M., Auner, H. W., Terpos, E. & Engelhardt, M., 2018, In : Haematologica. 103, 11, p. 1772-1784

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design

Drent, E., Poels, R., Mulders, M. J., van de Donk, N. W. C. J., Themeli, M., Lokhorst, H. M. & Mutis, T., 2018, In : PLoS ONE. 13, 5, p. e0197349

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients

Franssen, L. E., Nijhof, I. S., Bjorklund, C. C., Chiu, H., Doorn, R., Van Velzen, J., Emmelot, M., Van Kessel, B., Levin, M. D., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., Van Der Spek, E., Raymakers, R., Sonneveld, P., Zweegman, S. & 5 othersLokhorst, H. M., Thakurta, A., Qian, X., Mutis, T. & Van De Donk, N. W. C. J., 1 Sep 2018, In : Oncotarget. 9, 74, p. 34009-34021 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: Results from a phase ii trial

Dimopoulos, M., Weisel, K., van de Donk, N. W. C. J., Ramasamy, K., Gamberi, B., Streetly, M., Offidani, M., Bridoux, F., de la Rubia, J., Mateos, M-V., Ardizzoia, A., Kueenburg, E., Collins, S., di Micco, A., Rosettani, B., Li, Y., Bacon, P. & Sonneveld, P., 2018, In : Journal of Clinical Oncology. 36, 20, p. 2035-2043

Research output: Contribution to journalArticleAcademicpeer-review

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial

van de Donk, N. W. CJ., van der Holt, B., Minnema, M. C., Vellenga, E., Croockewit, S., Kersten, M. J., von dem Borne, P. A., Ypma, P., Schaafsma, R., de Weerdt, O., Klein, S. K., Delforge, M., Levin, M-D., Bos, G. M., Jie, K-S. G., Sinnige, H., Coenen, J. L. LM., de Waal, E. G., Zweegman, S., Sonneveld, P. & 1 othersLokhorst, H. M., 2018, In : The Lancet Haematology. 5, 10, p. e479-e492

Research output: Contribution to journalArticleAcademicpeer-review

2017

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

Franssen, L. E., Roeven, M. W. H., Hobo, W., Doorn, R., Oostvogels, R., Falkenburg, J. H. F., Van De Donk, N. W., Kester, M. G. D., Fredrix, H., Westinga, K., Slaper-Cortenbach, I., Spierings, E., Kersten, M. J., Dolstra, H., Mutis, T., Schaap, N. & Lokhorst, H. M., 1 Oct 2017, In : Bone Marrow Transplantation. 52, 10, p. 1378-1383 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization

Drent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J., Martens, A. C. M., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., Lokhorst, H. M. & Mutis, T., 2 Aug 2017, In : Molecular Therapy. 25, 8, p. 1946-1958 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

Could daratumumab be used to treat severe allergy?

Blankestijn, M. A., van de Donk, N. W. C. J., Sasser, K., Knulst, A. C. & Otten, H. G., May 2017, In : Journal of Allergy and Clinical Immunology. 139, 5, p. 1677-1678.e3

Research output: Contribution to journalArticleAcademicpeer-review

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Casneuf, T., Xu, X. S., Adams, H. C., Axel, A. E., Chiu, C., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., Lokhorst, H. M., van de Donk, N. W. C. J., Clemens, P. L. & Sasser, A. K., 24 Oct 2017, In : Blood. 1, 23, p. 2105-2114 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation

Cook, G., Iacobelli, S., van Biezen, A., Ziagkos, D., LeBlond, V., Abraham, J., McQuaker, G., Schoenland, S., Rambaldi, A., Halaburda, K., Rovira, M., Sica, S., Byrne, J., Sanz, R. G., Nagler, A., van de Donk, N. W. C. J., Sinisalo, M., Cook, M., Kröger, N., De Witte, T. & 2 othersMorris, C. & Garderet, L., Jan 2017, In : Haematologica. 102, 1, p. 160-167 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Krejcik, J., Frerichs, K. A., Nijhof, I. S., van Kessel, B., van Velzen, J. F., Bloem, A. C., Broekmans, M. E. C., Zweegman, S., van Meerloo, J., Musters, R. J. P., Poddighe, P. J., Groen, R. W. J., Chiu, C., Plesner, T., Lokhorst, H. M., Sasser, A. K., Mutis, T. & van de Donk, N. W. C. J., 15 Dec 2017, In : Clinical Cancer Research. 23, 24, p. 7498-7511 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., Oriol, A., Cavo, M., Ocio, E. M., Mateos, M. V., O'Donnell, E. K., Vij, R., Lokhorst, H. M., Van De Donk, N. W. C. J., Min, C., Mark, T. & 27 othersTuresson, I., Hansson, M., Ludwig, H., Jagannath, S., Delforge, M., Kyriakou, C., Hari, P., Mellqvist, U., Usmani, S. Z., Dytfeld, D., Badros, A. Z., Moreau, P., Kim, K., Otero, P. R., Lee, J. H., Shustik, C., Waller, D., Chng, W. J., Ozaki, S., Lee, J. J., De La Rubia, J., Eom, H. S., Rosinol, L., Lahuerta, J. J., Sureda, A., Kim, J. S. & Durie, B. G. M., 1 Nov 2017, In : Leukemia. 31, 11, p. 2443-2448 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

Primary cardiac lymphoma with central nervous system relapse

van Rooijen, C. R., Scholtens, A. M., de Jong, C. N., Saraber, C. E. & van de Donk, N. W. C. J., Sep 2017, In : Clinical case reports. 5, 9, p. 1454-1458 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Response to: Interference of daratumumab on the serum protein electrophoresis

McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T. & Sasser, A. K., 1 Feb 2017, In : Clinical Chemistry and Laboratory Medicine. 55, 2, p. e29-e30

Research output: Contribution to journalArticleAcademicpeer-review

2016

A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma

Franken, B., van de Donk, N. W. C. J., Cloos, J. C., Zweegman, S. & Lokhorst, H. M., Dec 2016, In : THERAPEUTIC ADVANCES IN HEMATOLOGY. 7, 6, p. 330-344

Research output: Contribution to journalArticleAcademicpeer-review

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Nijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., Zweegman, S., Chiu, C., Bloem, A. C., Mutis, T., Lokhorst, H. M., Sasser, A. K. & van de Donk, N. W. C. J., 18 Aug 2016, In : Blood. 128, 7, p. 959-970

Research output: Contribution to journalArticleAcademicpeer-review

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A., Gay, F., Laubach, J. P., Malavasi, F., Avet-Loiseau, H., Mateos, M-V., Sonneveld, P., Lokhorst, H. M. & Richardson, P. G., 11 Feb 2016, In : Blood. 127, 6, p. 681-695

Research output: Contribution to journalArticleAcademicpeer-review

Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., Ahmadi, T., Lokhorst, H. M., Mutis, T. & Sasser, A. K., 21 Jul 2016, In : Blood. 128, 3, p. 384-394

Research output: Contribution to journalArticleAcademicpeer-review

Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)

van de Donk, N., Otten, H. G., El Haddad, O., Axel, A., Sasser, A. K., Croockewit, S. & Jacobs, J. F. M., Jun 2016, In : Clinical Chemistry and Laboratory Medicine. 54, 6, p. 1105-1109

Research output: Contribution to journalArticleAcademicpeer-review

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Zweegman, S., van der Holt, B., Mellqvist, U-H., Salomo, M., Bos, G. M. J., Levin, M-D., Visser-Wisselaar, H., Hansson, M., van der Velden, A. W. G., Deenik, W., Gruber, A., Coenen, J. L. L. M., Plesner, T., Klein, S. K., Tanis, B. C., Szatkowski, D. L., Brouwer, R. E., Westerman, M., Leys, M. R. B. L., Sinnige, H. A. M. & 8 othersHaukas, E., van der Hem, K. G., Durian, M. F., Mattijssen, E. V. J. M., van de Donk, N. W. C. J., Stevens-Kroef, M. J. P. L., Sonneveld, P. & Waage, A., 3 Mar 2016, In : Blood. 127, 9, p. 1109-1116

Research output: Contribution to journalArticleAcademicpeer-review

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

McCudden, C., Axel, A. E., Slaets, D., Dejoie, T., Clemens, P. L., Frans, S., Bald, J., Plesner, T., Jacobs, J. F. M., van de Donk, N. W. C. J., Moreau, P., Schecter, J. M., Ahmadi, T. & Sasser, A. K., Jun 2016, In : Clinical Chemistry and Laboratory Medicine. 54, 6, p. 1095-1104

Research output: Contribution to journalArticleAcademicpeer-review

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., van Bueren, J. J. L., Ahmadi, T., Sasser, A. K., Lokhorst, H. M. & Parren, P. W. H. I., Mar 2016, In : Immunological Reviews. 270, 1, p. 95-112

Research output: Contribution to journalArticleAcademicpeer-review

Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution

Franssen, L. E., Raymakers, R. A. P., Buijs, A., Schmitz, M. F., van Dorp, S., Mutis, T., Lokhorst, H. M. & van de Donk, N. W. C. J., Nov 2016, In : European Journal of Haematology. 97, 5, p. 479-488

Research output: Contribution to journalArticleAcademicpeer-review

PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

Casneuf, T., Xu, X. S., Adams, H. . III., Axel, A., Verbist, B., Liu, K., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., Lokhorst, H., van de Donk, N. W., Clemens, P. L. & Sasser, A. K., Jun 2016, In : Haematologica. 101, p. 87-88

Research output: Contribution to journalArticleAcademicpeer-review

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Nijhof, I. S., Franssen, L. E., Levin, M-D., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., van der Spek, E., Ypma, P. F., Raymakers, R., van Spronsen, D-J., Westerweel, P. E., Oostvogels, R., van Velzen, J., van Kessel, B., Mutis, T., Sonneveld, P. & 3 othersZweegman, S., Lokhorst, H. M. & van de Donk, N. W. C. J., 10 Nov 2016, In : Blood. 128, 19, p. 2297-2306

Research output: Contribution to journalArticleAcademicpeer-review

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Moreau, P., van de Donk, N. W. C. J., Miguel, J. S., Lokhorst, H., Nahi, H., Ben-Yehuda, D., Cavo, M., Cook, G., Delforge, M., Einsele, H., Zweegman, S., Ludwig, H., Driessen, C., Palumbo, A., Facon, T., Plesner, T., Dimopoulos, M., Sondergeld, P., Sonneveld, P. & Mateos, M-V., May 2016, In : Drugs. 76, 8, p. 853-867

Research output: Contribution to journalArticleAcademicpeer-review

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Drent, E., Groen, R. W. J., Noort, W. A., Themeli, M., van Bueren, J. J. L., Parren, P. W. H. I., Kuball, J., Sebestyen, Z., Yuan, H., de Bruijn, J., van de Donk, N. W. C. J., Martens, A. C. M., Lokhorst, H. M. & Mutis, T., May 2016, In : Haematologica. 101, 5, p. 616-625

Research output: Contribution to journalArticleAcademicpeer-review

Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance

de Haart, S. J., Holthof, L., Noort, W. A., Minnema, M. C., Emmelot, M. E., Aarts-Riemens, T., Doshi, P., Sasser, K., Yuan, H., de Bruijn, J., Martens, A. C. M., van de Donk, N. W. C. J., Lokhorst, H. M., Groen, R. W. J. & Mutis, T., Aug 2016, In : Haematologica. 101, 8, p. E339-E343

Research output: Contribution to journalArticleAcademicpeer-review

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W-J., Moreau, P., Attal, M., Kyle, R. A., Caers, J., Hillengass, J., San Miguel, J., van de Donk, N. W. C. J., Einsele, H., Bladé, J., Durie, B. G. M., Goldschmidt, H., Mateos, M-V., Palumbo, A. & 1 othersOrlowski, R., 16 Jun 2016, In : Blood. 127, 24, p. 2955-62 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

2015

Chimere antigeenreceptoren als immuuntherapie voor hematologische maligniteiten

Drent, E., van de Donk, N. W. C. J., Lokhorst, H. M. & Mutis, T., 2015, In : Nederlands Tijdschrift voor Hematologie. 12, 8, p. 303-312

Research output: Contribution to journalArticleProfessional

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Nijhof, I. S., van Bueren, J. J. L., van Kessel, B., Andre, P., Morel, Y., Lokhorst, H. M., van de Donk, N. W. C. J., Parren, P. W. H. I. & Mutis, T., 2015, In : Haematologica. 100, 2, p. 263-268

Research output: Contribution to journalArticleAcademicpeer-review

De eerste HOVON- en European Myeloma Network-studie voor primaire plasmacelleukemie: HOVON 129

van de Donk, N. W. C. J., Sonneveld, P., Zweegman, S., Vellenga, E., Croockewit, S., Minnema, M. C. & Lokhorst, H. M., 2015, In : Nederlands Tijdschrift voor Hematologie. 12, 5, p. 190-193

Research output: Contribution to journalArticleProfessional

Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis

Slot, S., Smits, K., van de Donk, N. W. C. J., Witte, B. I., Raymakers, R., Janssen, J. J. W. M., Broers, A. E. C., te Boekhorst, P. A. W. & Zweegman, S., 2015, In : Bone Marrow Transplantation. 50, 11, p. 1424-1431

Research output: Contribution to journalArticleAcademicpeer-review

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., Bringhen, S., Beksac, M., Larocca, A., Hajek, R., Musto, P., Johnsen, H. E., Morabito, F., Ludwig, H., Cavo, M., Einsele, H. & 3 othersSonneveld, P., Dimopoulos, M. A. & Palumbo, A., 2015, In : Haematologica. 100, 10, p. 1254-1266

Research output: Contribution to journalArticleAcademicpeer-review

Monoclonal Antibodies in Myeloma

Sondergeld, P., van de Donk, N. W. C. J., Richardson, P. G. & Plesner, T., 2015, In : Clinical Advances in Hematology & Oncology. 13, 9, p. 599-609

Research output: Contribution to journalArticleAcademicpeer-review

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., Martens, A. C. M. & Mutis, T., 2015, In : Clinical Cancer Research. 21, 12, p. 2802-2810

Research output: Contribution to journalArticleAcademicpeer-review

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., van de Donk, N. W. C. J., Ahmadi, T., Khan, I., Uhlar, C. M., Wang, J., Sasser, A. K., Losic, N., Lisby, S., Basse, L., Brun, N. & 1 othersRichardson, P. G., 2015, In : New England Journal of Medicine. 373, 13, p. 1207-1219

Research output: Contribution to journalArticleAcademicpeer-review

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs

Franssen, L. E., van de Donk, N. W. C. J., Emmelot, M. E., Roeven, M. W. H., Schaap, N., Dolstra, H., Hobo, W., Lokhorst, H. M. & Mutis, T., 2015, In : Bone Marrow Transplantation. 50, 6, p. 822-828

Research output: Contribution to journalArticleAcademicpeer-review